Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
06 2021
Historique:
accepted: 28 10 2020
pubmed: 2 11 2020
medline: 2 7 2021
entrez: 1 11 2020
Statut: ppublish

Résumé

Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe and about potential changes over time. The aim of this retrospective study was to analyse the frequency of PCLs in the French Cutaneous Lymphoma Registry (GFELC) and to describe the demography of patients. Patients with a centrally validated diagnosis of primary PCL, diagnosed between 2005 and 2019, were included. The calculated incidence was unprecedently high at 1·06 per 100 000 person-years. The number of included patients increased yearly. Most PCL subtypes were more frequent in male patients, diagnosed at a median age of 60 years. The relative frequency of rare CTCL remained stable, the proportion of classical mycosis fungoides (MF) decreased, and the frequency of its variants (e.g. folliculotropic MF) increased. Similar patterns were observed for CBCL; for example, the proportion of marginal-zone CBCL increased over time. Changes in PCL frequencies may be explained by the emergence of new diagnostic criteria and better description of the entities in the most recent PCL classification. Moreover, we propose that an algorithm should be developed to confirm the diagnosis of PCL by central validation of the cases.

Sections du résumé

BACKGROUND
Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe and about potential changes over time.
OBJECTIVES
The aim of this retrospective study was to analyse the frequency of PCLs in the French Cutaneous Lymphoma Registry (GFELC) and to describe the demography of patients.
METHODS
Patients with a centrally validated diagnosis of primary PCL, diagnosed between 2005 and 2019, were included.
RESULTS
The calculated incidence was unprecedently high at 1·06 per 100 000 person-years. The number of included patients increased yearly. Most PCL subtypes were more frequent in male patients, diagnosed at a median age of 60 years. The relative frequency of rare CTCL remained stable, the proportion of classical mycosis fungoides (MF) decreased, and the frequency of its variants (e.g. folliculotropic MF) increased. Similar patterns were observed for CBCL; for example, the proportion of marginal-zone CBCL increased over time.
CONCLUSIONS
Changes in PCL frequencies may be explained by the emergence of new diagnostic criteria and better description of the entities in the most recent PCL classification. Moreover, we propose that an algorithm should be developed to confirm the diagnosis of PCL by central validation of the cases.

Identifiants

pubmed: 33131055
doi: 10.1111/bjd.19644
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1059-1067

Subventions

Organisme : European Society for Medical Oncology
ID : Translational Research Fellowship

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 British Association of Dermatologists.

Références

Abbott RA, Aldridge C, Dojcinov S, Piguet V. Incidence of primary cutaneous T-cell lymphoma in Wales. Br J Dermatol 2013; 169:1366-7.
Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. Br J Dermatol 2009; 160:376-9.
Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute’s Surveillance, Epidemiology, and End Results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol 2005; 23:7246-8.
Beylot-Barry M, Vergier B, Masquelier B et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999; 23:1208-16.
Bouaziz JD, Bastuji-Garin S, Poszepczynska-Guigne E et al. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients. Br J Dermatol 2006; 154:1206-7.
Grange F, Hedelin G, Joly P et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas. Blood 1999; 93:3637-42.
Laban E, Beylot-Barry M, Ortonne N et al. [Cutaneous lymphoproliferations: proposal for the use of diagnostic algorithms based on 2760 cases of cutaneous lymphoproliferations taken from the INCa networks (LYMPHOPATH and GFELC) over a two-year period]. Ann Pathol 2015; 35:131-47 (in French).
Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113:5064-73.
Markova A, Weinstock MA. Trends in cutaneous lymphoma epidemiology. Clin Lymphoma Myeloma Leuk 2010; 10 (Suppl. 2):S63-6.
Dobos G, Pohrt A, Ram-Wolff C et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers (Basel) 2020; 12:2921.
Hamada T, Iwatsuki K. Cutaneous lymphoma in Japan: a nationwide study of 1733 patients. J Dermatol 2014; 41:3-10.
Scarisbrick JJ, Prince HM, Vermeer MH et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 2015; 33:3766-73.
Salah E. Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder: where do we stand? A systematic review. J Dtsch Dermatol Ges 2019; 17:123-36.
Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768-85.
Willemze R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133:1703-14.
Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:479-84.
Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713-22.
Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk 2012; 12:291-6.
Gerami P, Rosen S, Kuzel T et al. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol 2008; 144:738-46.
Hodak E, Amitay-Laish I, Atzmony L et al. New insights into folliculotropic mycosis fungoides (FMF): a single-centre experience. J Am Acad Dermatol 2016; 75:347-55.
Park JH, Han JH, Kang HY et al. Expression of follicular helper T-cell markers in primary cutaneous T-cell lymphoma. Am J Dermatopathol 2014; 36:465-70.
Senff NJ, Hoefnagel JJ, Jansen PM et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007; 25:1581-7.
Menguy S, Beylot-Barry M, Parrens M et al. Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases. Histopathology 2019; 74:1067-80.
Penate Y, Servitje O, Machan S et al. The first year of the AEVD Primary Cutaneous Lymphoma Registry. Actas Dermosifiliogr 2018; 109:610-6.
Sonigo G, Battistella M, Beylot-Barry M et al. HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. Blood 2020; 135:1058-61.
Scarisbrick JJ, Quaglino P, Prince HM et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019; 181:350-7.
Kheterpal MK, Dai J, Geller S et al. Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin. J Am Acad Dermatol 2019; 81:970-6.

Auteurs

G Dobos (G)

Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.
INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.
Université de Paris, Paris, France.

A de Masson (A)

Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.
INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.
Université de Paris, Paris, France.

C Ram-Wolff (C)

Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.
INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.
Université de Paris, Paris, France.

M Beylot-Barry (M)

Dermatology Department, Université de Bordeaux, Bordeaux, France.

A Pham-Ledard (A)

Dermatology Department, Université de Bordeaux, Bordeaux, France.

N Ortonne (N)

Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France.

S Ingen-Housz-Oro (S)

Dermatology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France.

M Battistella (M)

INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.
Université de Paris, Paris, France.
Pathology Department, Saint-Louis Hospital, AP-HP, Paris, France.

M d'Incan (M)

Dermatology and Cutaneous Oncology, Estaing University Hospital, Université de Clermont-Ferrand, Clermont-Ferrand, France.

J Rouanet (J)

Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France.

F Franck (F)

Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France.

M D Vignon-Pennamen (MD)

Pathology Department, Saint-Louis Hospital, AP-HP, Paris, France.

N Franck (N)

Dermatology Department, Cochin Hospital, AP-HP, Paris, France.

A Carlotti (A)

Pathology Department, Cochin Hospital, AP-HP, Paris, France.

S Boulinguez (S)

Dermatology Department, Cahors Hospital, Toulouse, France.

L Lamant (L)

Pathology and Cytopathology Department, Institut Universitaire du Cancer Toulouse, Toulouse, France.

T Petrella (T)

Pathology Department, Dijon Bourgogne University Hospital, Dijon, France.

S Dalac (S)

Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France.

P Joly (P)

Dermatology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France.

P Courville (P)

Pathology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France.

J Rivet (J)

Dermatology Department, Université de Bordeaux, Bordeaux, France.
Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France.

O Dereure (O)

Dermatology Department, Montpellier University Hospital, Montpellier, France.

F Amatore (F)

Department of Dermatology and Oncodermatology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France.

S Taix (S)

Department of Pathology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France.

F Grange (F)

Dermatology Department, Robert Debré University Hospital, Reims, France.

A Durlach (A)

Pathology Department, Reims University Hospital, Reims, France.

G Quéreux (G)

Dermatology Department, Nantes University Hospital, Nantes, France.

N Josselin (N)

Pathology Department, Nantes University Hospital, Nantes, France.

I Moulonguet (I)

Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.

L Mortier (L)

Dermatology Department, Claude Huriez University Hospital, INSERM U1189, Université de Lille, Lille, France.

R Dubois (R)

Pathology Department, Claude Huriez University Hospital, Lille, France.

E Maubec (E)

Dermatology Department, Avicenne Hospital, AP-HP, Paris, France.

L Laroche (L)

Dermatology Department, Avicenne Hospital, AP-HP, Paris, France.

L Michel (L)

INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.
Université de Paris, Paris, France.

I Templier (I)

Dermatology Department, Grenoble University Hospital, Grenoble, France.

S Barete (S)

Dermatology Department, Pité-Salpêtrière Hospital, AP-HP, Paris, France.

C Nardin (C)

Dermatology Department, Minjoz Hospital, Besancon, France, INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France.

O Augereau (O)

Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France.

B Vergier (B)

Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France.

M Bagot (M)

Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.
INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.
Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH